Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 197

1.

Hyperpolarized 13C MRI: Path to Clinical Translation in Oncology.

Kurhanewicz J, Vigneron DB, Ardenkjaer-Larsen JH, Bankson JA, Brindle K, Cunningham CH, Gallagher FA, Keshari KR, Kjaer A, Laustsen C, Mankoff DA, Merritt ME, Nelson SJ, Pauly JM, Lee P, Ronen S, Tyler DJ, Rajan SS, Spielman DM, Wald L, Zhang X, Malloy CR, Rizi R.

Neoplasia. 2019 Jan;21(1):1-16. doi: 10.1016/j.neo.2018.09.006. Epub 2018 Nov 23. Review.

2.

Test-retest reproducibility of FDG-PET/CT uptake in cancer patients within a qualified and calibrated local network.

Kurland BF, Peterson LM, Shields AT, Lee JH, Byrd DW, Novakova-Jiresova A, Muzi M, Specht JM, Mankoff DA, Linden HM, Kinahan PE.

J Nucl Med. 2018 Oct 25. pii: jnumed.118.209544. doi: 10.2967/jnumed.118.209544. [Epub ahead of print]

PMID:
30361381
3.

Correction to: a Phase 2 Study of 16α-[18F]-Fluoro-17β-Estradiol Positron Emission Tomography (FES-PET) as a Marker of Hormone Sensitivity in Metastatic Breast Cancer (MBC).

Peterson LM, Kurland BF, Schubert EK, Link JM, Gadi VK, Specht JM, Eary JF, Porter P, Shankar LK, Mankoff DA, Linden HM.

Mol Imaging Biol. 2018 Oct 15. doi: 10.1007/s11307-018-1287-7. [Epub ahead of print]

PMID:
30324461
4.

The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Treatment of Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial.

Andriole GL, Kostakoglu L, Chau A, Duan F, Mahmood U, Mankoff DA, Schuster DM, Siegel BA; LOCATE Study Group.

J Urol. 2019 Feb;201(2):322-331. doi: 10.1016/j.juro.2018.08.050.

PMID:
30179618
5.

Glutamate-Weighted Chemical Exchange Saturation Transfer Magnetic Resonance Imaging Detects Glutaminase Inhibition in a Mouse Model of Triple-Negative Breast Cancer.

Zhou R, Bagga P, Nath K, Hariharan H, Mankoff DA, Reddy R.

Cancer Res. 2018 Oct 1;78(19):5521-5526. doi: 10.1158/0008-5472.CAN-17-3988. Epub 2018 Aug 2.

PMID:
30072394
6.

Impact of Early Radiology Research Experiences on Medical Student Perceptions of Radiology and Research.

Shah P, Sheng M, Mankoff DA, Trerotola SO, Galperin-Aizenberg M, Katz SI, Barbosa EJM, Nachiappan AC.

Curr Probl Diagn Radiol. 2018 May 24. pii: S0363-0188(18)30088-4. doi: 10.1067/j.cpradiol.2018.05.011. [Epub ahead of print]

PMID:
30068477
7.

Imaging Cancer Metabolism: Underlying Biology and Emerging Strategies.

Pantel AR, Ackerman D, Lee SC, Mankoff DA, Gade TP.

J Nucl Med. 2018 Sep;59(9):1340-1349. doi: 10.2967/jnumed.117.199869. Epub 2018 Jul 24.

PMID:
30042161
8.

The Use of Quantitative Imaging in Radiation Oncology: A Quantitative Imaging Network (QIN) Perspective.

Press RH, Shu HG, Shim H, Mountz JM, Kurland BF, Wahl RL, Jones EF, Hylton NM, Gerstner ER, Nordstrom RJ, Henderson L, Kurdziel KA, Vikram B, Jacobs MA, Holdhoff M, Taylor E, Jaffray DA, Schwartz LH, Mankoff DA, Kinahan PE, Linden HM, Lambin P, Dilling TJ, Rubin DL, Hadjiiski L, Buatti JM.

Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):1219-1235. doi: 10.1016/j.ijrobp.2018.06.023. Epub 2018 Jun 30. Review.

PMID:
29966725
9.

PET imaging for assessing tumor response to therapy.

Mankoff DA, Katz SI.

J Surg Oncol. 2018 Aug;118(2):362-373. doi: 10.1002/jso.25114. Epub 2018 Jun 24. Review.

PMID:
29938396
10.

A PET imaging agent for evaluating PARP-1 expression in ovarian cancer.

Makvandi M, Pantel A, Schwartz L, Schubert E, Xu K, Hsieh CJ, Hou C, Kim H, Weng CC, Winters H, Doot R, Farwell MD, Pryma DA, Greenberg RA, Mankoff DA, Simpkins F, Mach RH, Lin LL.

J Clin Invest. 2018 May 1;128(5):2116-2126. doi: 10.1172/JCI97992. Epub 2018 Apr 16.

11.

FDG PET and FES PET Predict PFS on Endocrine Therapy-Response.

Kurland BF, Peterson LM, Linden HM, Mankoff DA.

Clin Cancer Res. 2018 Jan 1;24(1):249-250. doi: 10.1158/1078-0432.CCR-17-2980. No abstract available.

12.

Imaging Neoadjuvant Therapy Response in Breast Cancer.

Fowler AM, Mankoff DA, Joe BN.

Radiology. 2017 Nov;285(2):358-375. doi: 10.1148/radiol.2017170180. Review.

PMID:
29045232
13.

Bacterial infection imaging with [18F]fluoropropyl-trimethoprim.

Sellmyer MA, Lee I, Hou C, Weng CC, Li S, Lieberman BP, Zeng C, Mankoff DA, Mach RH.

Proc Natl Acad Sci U S A. 2017 Aug 1;114(31):8372-8377. doi: 10.1073/pnas.1703109114. Epub 2017 Jul 17.

14.

FDG PET and FES PET Predict PFS on Endocrine Therapy-Response.

Kurland BF, Linden HM, Mankoff DA.

Clin Cancer Res. 2017 Jul 1;23(13):3475. doi: 10.1158/1078-0432.CCR-17-0479. No abstract available.

15.

[18F](2S,4R)4-Fluoroglutamine PET Detects Glutamine Pool Size Changes in Triple-Negative Breast Cancer in Response to Glutaminase Inhibition.

Zhou R, Pantel AR, Li S, Lieberman BP, Ploessl K, Choi H, Blankemeyer E, Lee H, Kung HF, Mach RH, Mankoff DA.

Cancer Res. 2017 Mar 15;77(6):1476-1484. doi: 10.1158/0008-5472.CAN-16-1945. Epub 2017 Feb 15.

16.

A virtual clinical trial comparing static versus dynamic PET imaging in measuring response to breast cancer therapy.

Wangerin KA, Muzi M, Peterson LM, Linden HM, Novakova A, Mankoff DA, Kinahan PE.

Phys Med Biol. 2017 May 7;62(9):3639-3655. doi: 10.1088/1361-6560/aa6023. Epub 2017 Feb 13.

17.

Quantitative PET Reporter Gene Imaging with [11C]Trimethoprim.

Sellmyer MA, Lee I, Hou C, Lieberman BP, Zeng C, Mankoff DA, Mach RH.

Mol Ther. 2017 Jan 4;25(1):120-126. doi: 10.1016/j.ymthe.2016.10.018. Epub 2017 Jan 4.

18.

Making Molecular Imaging a Clinical Tool for Precision Oncology: A Review.

Mankoff DA, Farwell MD, Clark AS, Pryma DA.

JAMA Oncol. 2017 May 1;3(5):695-701. doi: 10.1001/jamaoncol.2016.5084. Review.

PMID:
28033451
19.

Molecular Imaging and Precision Medicine in Breast Cancer.

Chudgar AV, Mankoff DA.

PET Clin. 2017 Jan;12(1):39-51. doi: 10.1016/j.cpet.2016.08.001. Epub 2016 Oct 4. Review.

PMID:
27863565
20.

ACR Appropriateness Criteria® Stage I Breast Carcinoma.

Huynh PT, Lemeshko SV, Mahoney MC, Newell MS, Bailey L, Barke LD, D'Orsi C, Harvey JA, Hayes MK, Jokich PM, Lee SJ, Lehman CD, Mainiero MB, Mankoff DA, Patel SB, Reynolds HE, Sutherland ML, Haffty BG.

J Am Coll Radiol. 2016 Nov;13(11S):e53-e57. doi: 10.1016/j.jacr.2016.09.024. Review.

PMID:
27814824
21.

ACR Appropriateness Criteria Stage I Breast Cancer: Initial Workup and Surveillance for Local Recurrence and Distant Metastases in Asymptomatic Women.

Moy L, Newell MS, Mahoney MC, Bailey L, Barke LD, Carkaci S, D'Orsi C, Goyal S, Haffty BG, Harvey JA, Hayes MK, Jokich PM, Lee SJ, Mainiero MB, Mankoff DA, Patel SB, Yepes MM.

J Am Coll Radiol. 2016 Nov;13(11S):e43-e52. doi: 10.1016/j.jacr.2016.09.023. Review.

PMID:
27814823
22.

ACR Appropriateness Criteria Palpable Breast Masses.

Harvey JA, Mahoney MC, Newell MS, Bailey L, Barke LD, D'Orsi C, Hayes MK, Jokich PM, Lee SJ, Lehman CD, Mainiero MB, Mankoff DA, Patel SB, Reynolds HE, Sutherland ML, Haffty BG.

J Am Coll Radiol. 2016 Nov;13(11S):e31-e42. doi: 10.1016/j.jacr.2016.09.022. Review.

PMID:
27814822
23.

ACR Appropriateness Criteria Breast Cancer Screening.

Mainiero MB, Lourenco A, Mahoney MC, Newell MS, Bailey L, Barke LD, D'Orsi C, Harvey JA, Hayes MK, Huynh PT, Jokich PM, Lee SJ, Lehman CD, Mankoff DA, Nepute JA, Patel SB, Reynolds HE, Sutherland ML, Haffty BG.

J Am Coll Radiol. 2016 Nov;13(11S):R45-R49. doi: 10.1016/j.jacr.2016.09.021. Review.

PMID:
27814813
24.

Repeatability of 18F-FLT PET in a Multicenter Study of Patients with High-Grade Glioma.

Lodge MA, Holdhoff M, Leal JP, Bag AK, Nabors LB, Mintz A, Lesser GJ, Mankoff DA, Desai AS, Mountz JM, Lieberman FS, Fisher JD, Desideri S, Ye X, Grossman SA, Schiff D, Wahl RL.

J Nucl Med. 2017 Mar;58(3):393-398. doi: 10.2967/jnumed.116.178434. Epub 2016 Sep 29.

25.

Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer.

Kurland BF, Peterson LM, Lee JH, Schubert EK, Currin ER, Link JM, Krohn KA, Mankoff DA, Linden HM.

Clin Cancer Res. 2017 Jan 15;23(2):407-415. doi: 10.1158/1078-0432.CCR-16-0362. Epub 2016 Jun 24.

26.

18F-Fluoroestradiol PET: Current Status and Potential Future Clinical Applications.

Liao GJ, Clark AS, Schubert EK, Mankoff DA.

J Nucl Med. 2016 Aug;57(8):1269-75. doi: 10.2967/jnumed.116.175596. Epub 2016 Jun 15. Review.

27.

Molecular imaging to guide systemic cancer therapy: Illustrative examples of PET imaging cancer biomarkers.

Pantel AR, Mankoff DA.

Cancer Lett. 2017 Feb 28;387:25-31. doi: 10.1016/j.canlet.2016.05.008. Epub 2016 May 16. Review.

28.

ACRIN 6684: Assessment of Tumor Hypoxia in Newly Diagnosed Glioblastoma Using 18F-FMISO PET and MRI.

Gerstner ER, Zhang Z, Fink JR, Muzi M, Hanna L, Greco E, Prah M, Schmainda KM, Mintz A, Kostakoglu L, Eikman EA, Ellingson BM, Ratai EM, Sorensen AG, Barboriak DP, Mankoff DA; ACRIN 6684 Trial Group.

Clin Cancer Res. 2016 Oct 15;22(20):5079-5086. Epub 2016 May 16.

29.

[(18)F]FluorThanatrace uptake as a marker of PARP1 expression and activity in breast cancer.

Edmonds CE, Makvandi M, Lieberman BP, Xu K, Zeng C, Li S, Hou C, Lee H, Greenberg RA, Mankoff DA, Mach RH.

Am J Nucl Med Mol Imaging. 2016 Jan 28;6(1):94-101. eCollection 2016.

30.

Temporal Heterogeneity of Estrogen Receptor Expression in Bone-Dominant Breast Cancer: 18F-Fluoroestradiol PET Imaging Shows Return of ER Expression.

Currin E, Peterson LM, Schubert EK, Link JM, Krohn KA, Livingston RB, Mankoff DA, Linden HM.

J Natl Compr Canc Netw. 2016 Feb;14(2):144-7.

31.

Novel Strategies for Breast Cancer Imaging: New Imaging Agents to Guide Treatment.

McDonald ES, Mankoff DA, Mach RH.

J Nucl Med. 2016 Feb;57 Suppl 1:69S-74S. doi: 10.2967/jnumed.115.157925. Review.

32.

Effect of 18F-FDG uptake time on lesion detectability in PET imaging of early stage breast cancer.

Wangerin KA, Muzi M, Peterson LM, Linden HM, Novakova A, O'Sullivan F, Kurland BF, Mankoff DA, Kinahan PE.

Tomography. 2015 Sep;1(1):53-60.

33.

Quantitative Imaging in Cancer Clinical Trials.

Yankeelov TE, Mankoff DA, Schwartz LH, Lieberman FS, Buatti JM, Mountz JM, Erickson BJ, Fennessy FM, Huang W, Kalpathy-Cramer J, Wahl RL, Linden HM, Kinahan PE, Zhao B, Hylton NM, Gillies RJ, Clarke L, Nordstrom R, Rubin DL.

Clin Cancer Res. 2016 Jan 15;22(2):284-90. doi: 10.1158/1078-0432.CCR-14-3336. Review.

34.

The pre-clinical characterization of an alpha-emitting sigma-2 receptor targeted radiotherapeutic.

Makvandi M, Lieberman BP, LeGeyt B, Hou C, Mankoff DA, Mach RH, Pryma DA.

Nucl Med Biol. 2016 Jan;43(1):35-41. doi: 10.1016/j.nucmedbio.2015.10.001. Epub 2015 Oct 22.

PMID:
26702785
35.

Development of Companion Diagnostics.

Mankoff DA, Edmonds CE, Farwell MD, Pryma DA.

Semin Nucl Med. 2016 Jan;46(1):47-56. doi: 10.1053/j.semnuclmed.2015.09.002. Review.

36.

Precise Localization of Occult Gastrointestinal Hemorrhage Using Dynamic SPECT/CT.

Murrey DA Jr, Hall NC, Wright CL, Mankoff DA.

Clin Nucl Med. 2016 Jan;41(1):46-9. doi: 10.1097/RLU.0000000000001014.

PMID:
26571449
37.

The contribution of physics to Nuclear Medicine: physicians' perspective on future directions.

Mankoff DA, Pryma DA.

EJNMMI Phys. 2014 Dec;1(1):5. doi: 10.1186/2197-7364-1-5. Epub 2014 May 1.

38.

Multicenter Clinical Trials Using 18F-FDG PET to Measure Early Response to Oncologic Therapy: Effects of Injection-to-Acquisition Time Variability on Required Sample Size.

Kurland BF, Muzi M, Peterson LM, Doot RK, Wangerin KA, Mankoff DA, Linden HM, Kinahan PE.

J Nucl Med. 2016 Feb;57(2):226-30. doi: 10.2967/jnumed.115.162289. Epub 2015 Oct 22.

39.

A Phase II Study of 3'-Deoxy-3'-18F-Fluorothymidine PET in the Assessment of Early Response of Breast Cancer to Neoadjuvant Chemotherapy: Results from ACRIN 6688.

Kostakoglu L, Duan F, Idowu MO, Jolles PR, Bear HD, Muzi M, Cormack J, Muzi JP, Pryma DA, Specht JM, Hovanessian-Larsen L, Miliziano J, Mallett S, Shields AF, Mankoff DA; ACRIN 668 Investigative Team.

J Nucl Med. 2015 Nov;56(11):1681-9. doi: 10.2967/jnumed.115.160663. Epub 2015 Sep 10.

40.

Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging Study.

Liu L, Collier AC, Link JM, Domino KB, Mankoff DA, Eary JF, Spiekerman CF, Hsiao P, Deo AK, Unadkat JD.

Drug Metab Dispos. 2015 Nov;43(11):1795-804. doi: 10.1124/dmd.114.058685. Epub 2015 Sep 9.

41.

How Imaging Biomarkers Can Inform Clinical Trials and Clinical Practice in the Era of Targeted Cancer Therapy.

Farwell MD, Clark AS, Mankoff DA.

JAMA Oncol. 2015 Jul;1(4):421-2. doi: 10.1001/jamaoncol.2015.0667. No abstract available.

PMID:
26181243
42.

18F-Fluoromisonidazole Quantification of Hypoxia in Human Cancer Patients Using Image-Derived Blood Surrogate Tissue Reference Regions.

Muzi M, Peterson LM, O'Sullivan JN, Fink JR, Rajendran JG, McLaughlin LJ, Muzi JP, Mankoff DA, Krohn KA.

J Nucl Med. 2015 Aug;56(8):1223-8. doi: 10.2967/jnumed.115.158717. Epub 2015 Jun 25.

43.

The Value of Establishing the Quantitative Accuracy of PET/CT Imaging.

Kinahan PE, Mankoff DA, Linden HM.

J Nucl Med. 2015 Aug;56(8):1133-4. doi: 10.2967/jnumed.115.159178. Epub 2015 Jun 18. No abstract available.

44.

How Imaging Can Impact Clinical Trial Design: Molecular Imaging as a Biomarker for Targeted Cancer Therapy.

Mankoff DA, Farwell MD, Clark AS, Pryma DA.

Cancer J. 2015 May-Jun;21(3):218-24. doi: 10.1097/PPO.0000000000000116. Review.

PMID:
26049702
45.

Choosing a single target as a biomarker or therapeutic using radioactive probes.

Eckelman WC, Mankoff DA.

Nucl Med Biol. 2015 May;42(5):421-425. doi: 10.1016/j.nucmedbio.2015.01.005. Epub 2015 Jan 28. Review. No abstract available.

PMID:
25684651
46.

Castration-resistant prostate cancer bone metastasis response measured by 18F-fluoride PET after treatment with dasatinib and correlation with progression-free survival: results from American College of Radiology Imaging Network 6687.

Yu EY, Duan F, Muzi M, Deng X, Chin BB, Alumkal JJ, Taplin ME, Taub JM, Herman B, Higano CS, Doot RK, Hartfeil D, Febbo PG, Mankoff DA.

J Nucl Med. 2015 Mar;56(3):354-60. doi: 10.2967/jnumed.114.146936. Epub 2015 Jan 29.

47.

ACR Appropriateness Criteria stage I breast cancer: initial workup and surveillance for local recurrence and distant metastases in asymptomatic women.

Moy L, Newell MS, Mahoney MC, Bailey L, Barke LD, Carkaci S, D'Orsi C, Goyal S, Haffty BG, Harvey JA, Hayes MK, Jokich PM, Lee SJ, Mainiero MB, Mankoff DA, Patel SB, Yepes MM.

J Am Coll Radiol. 2014 Dec;11(12 Pt A):1160-8. doi: 10.1016/j.jacr.2014.08.020. Epub 2014 Oct 23.

PMID:
25444069
48.

VOXEL-LEVEL MAPPING OF TRACER KINETICS IN PET STUDIES: A STATISTICAL APPROACH EMPHASIZING TISSUE LIFE TABLES.

O'Sullivan F, Muzi M, Mankoff DA, Eary JF, Spence AM, Krohn KA.

Ann Appl Stat. 2014 Jun 1;8(2):1065-1094.

49.
50.

PET/CT imaging in cancer: current applications and future directions.

Farwell MD, Pryma DA, Mankoff DA.

Cancer. 2014 Nov 15;120(22):3433-45. doi: 10.1002/cncr.28860. Epub 2014 Jun 19. Review.

Supplemental Content

Loading ...
Support Center